{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:05:53Z","timestamp":1783667153212,"version":"3.55.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.05.041","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:53:56Z","timestamp":1656939236000},"page":"234-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon?"],"prefix":"10.1016","volume":"172","author":[{"given":"Rajshekhar","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ejca.2022.05.041_bib1","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","article-title":"The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer","volume":"312","author":"Feinstein","year":"1985","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2022.05.041_bib2","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146949","article-title":"Changing patterns of symptomatic myeloma after the implementation of the 2014 IMWG diagnostic criteria and reduced early mortality","volume":"138","author":"Kastritis","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2022.05.041_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-141511","article-title":"The impact of S-Li-M criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcomes from the Australian and New Zealand myeloma and related diseases registry (MRDR)","volume":"136","author":"Ho","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.ejca.2022.05.041_bib4","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2022.05.041_bib5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.ejca.2022.05.041_bib6","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ejca.2022.05.041_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ejca.2022.05.041_bib8","first-page":"438","volume":"369","author":"Mateos","year":"2013"},{"issue":"11","key":"10.1016\/j.ejca.2022.05.041_bib9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2022.05.041_bib10","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2022.05.041_bib11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2022.05.041_bib12","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1080\/10428194.2021.1938032","article-title":"The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt","volume":"62","author":"Mohyuddin","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.ejca.2022.05.041_bib13","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/bjh.18102","article-title":"Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials","volume":"197","author":"Soomro","year":"2022","journal-title":"Br J Haematol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:01Z","timestamp":1760733481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":13,"alternative-id":["S0959804922003288"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.041","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}